Trial Profile
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Providence Health & Services
- 19 May 2021 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2019 Planned number of patients changed from 18 to 28.
- 25 Jun 2018 Planned number of patients changed from 6 to 18.